Fatty Liver

"Fatty Liver" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Descriptor ID	D005234
MeSH Number(s)	C06.552.241
Concept/Terms	Fatty Liver Fatty Liver Liver, Fatty Steatohepatitis Steatohepatitis Steatohepatitides Steatosis of Liver Visceral Steatosis Steatoses, Visceral Steatosis, Visceral Visceral Steatoses Liver Steatosis Liver Steatoses Steatoses, Liver Steatosis, Liver

Below are MeSH descriptors whose meaning is more general than "Fatty Liver".

Diseases [C]
Digestive System Diseases [C06]
Liver Diseases [C06.552]
Fatty Liver [C06.552.241]

Below are MeSH descriptors whose meaning is more specific than "Fatty Liver".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Fatty Liver" by people in this website by year, and whether "Fatty Liver" was a major or minor topic of these publications.

Bar chart showing 63 publications over 21 distinct years, with a maximum of 6 publications in 2011 and 2013 and 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2004	2	0	2
2005	1	3	4
2008	2	2	4
2009	4	0	4
2010	0	2	2
2011	5	1	6
2012	1	1	2
2013	3	3	6
2014	2	0	2
2015	3	1	4
2016	4	2	6
2017	3	2	5
2018	1	0	1
2019	1	0	1
2020	2	0	2
2021	1	1	2
2022	1	1	2
2023	2	0	2
2024	1	3	4
2025	1	0	1

Below are the most recent publications written about "Fatty Liver" by people in Profiles.

Colletta A, Cooper KM, Placentino G, Devuni D, Colletta C. Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes. Front Endocrinol (Lausanne). 2025; 16:1531295.

View in: PubMed
Friedline RH, Noh HL, Suk S, Albusharif M, Dagdeviren S, Saengnipanthkul S, Kim B, Kim AM, Kim LH, Tauer LA, Baez Torres NM, Choi S, Kim BY, Rao SD, Kasina K, Sun C, Toles BJ, Zhou C, Li Z, Benoit VM, Patel PR, Zheng DXT, Inashima K, Beaverson A, Hu X, Tran DA, Muller W, Greiner DL, Mullen AC, Lee KW, Kim JK. IFN?-IL12 axis regulates intercellular crosstalk in metabolic dysfunction-associated steatotic liver disease. Nat Commun. 2024 Jun 29; 15(1):5506.

View in: PubMed
Babuta M, Nagesh PT, Datta AA, Remotti V, Zhuang Y, Mehta J, Lami F, Wang Y, Szabo G. Combined Insults of a MASH Diet and Alcohol Binges Activate Intercellular Communication and Neutrophil Recruitment via the NLRP3-IL-1? Axis in the Liver. Cells. 2024 06 01; 13(11).

View in: PubMed
Jiang S, Yuan T, Rosenberger FA, Mourier A, Dragano NRV, Kremer LS, Rubalcava-Gracia D, Hansen FM, Borg M, Mennuni M, Filograna R, Alsina D, Misic J, Koolmeister C, Papadea P, de Angelis MH, Ren L, Andersson O, Unger A, Bergbrede T, Di Lucrezia R, Wibom R, Zierath JR, Krook A, Giavalisco P, Mann M, Larsson NG. Inhibition of mammalian mtDNA transcription acts paradoxically to reverse diet-induced hepatosteatosis and obesity. Nat Metab. 2024 Jun; 6(6):1024-1035.

View in: PubMed
Liu Z, Dai J, Liu R, Shen Z, Huang A, Huang Y, Wang L, Chen P, Zhou Z, Xiao H, Chen X, Yang X. Complex insoluble dietary fiber alleviates obesity and liver steatosis, and modulates the gut microbiota in C57BL/6J mice fed a high-fat diet. J Sci Food Agric. 2024 Jul; 104(9):5462-5473.

View in: PubMed
Hess A, Gentile SD, Ben Saad A, Rahman RU, Habboub T, Pratt DS, Mullen AC. Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease. EMBO J. 2023 Dec 11; 42(24):e113898.

View in: PubMed
Ferreira V, Folgueira C, Garc?a-Altares M, Guill?n M, Ru?z-Rosario M, DiNunzio G, Garcia-Martinez I, Alen R, Bookmeyer C, Jones JG, Cigudosa JC, L?pez-Larrubia P, Correig-Blanchar X, Davis RJ, Sabio G, Rada P, Valverde ?M. Hypothalamic JNK1-hepatic fatty acid synthase axis mediates a metabolic rewiring that prevents hepatic steatosis in male mice treated with olanzapine via intraperitoneal: Additional effects of PTP1B inhibition. Redox Biol. 2023 07; 63:102741.

View in: PubMed
Morel C, Chowdhary V, Thevkar Nagesh P, Ribeiro M, Hawryluk D, Catalano D, Adorini L, Szabo G. Altered ethanol metabolism and increased oxidative stress enhance alcohol-associated liver injury in farnesoid X receptor-deficient mice. Liver Int. 2023 01; 43(1):100-114.

View in: PubMed
Mainz RE, Albers S, Haque M, Sonntag R, Treichel NS, Clavel T, Latz E, Schneider KM, Trautwein C, Otto T. NLRP6 Inflammasome Modulates Disease Progression in a Chronic-Plus-Binge Mouse Model of Alcoholic Liver Disease. Cells. 2022 01 06; 11(2).

View in: PubMed
Tsagkaraki E, Nicoloro SM, DeSouza T, Solivan-Rivera J, Desai A, Lifshitz LM, Shen Y, Kelly M, Guilherme A, Henriques F, Amrani N, Ibraheim R, Rodriguez TC, Luk K, Maitland S, Friedline RH, Tauer L, Hu X, Kim JK, Wolfe SA, Sontheimer EJ, Corvera S, Czech MP. CRISPR-enhanced human adipocyte browning as cell therapy for metabolic disease. Nat Commun. 2021 Nov 26; 12(1):6931.

View in: PubMed

People

Explore

Similar Concepts

Top Journals